RGS12 Antibody

What are the primary applications of RGS12 antibody in research settings?

RGS12 antibody (such as 29803-1-AP) can be used in multiple experimental applications including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC), and ELISA. The antibody shows reactivity with human and mouse samples, making it versatile for various model systems. Optimal dilution ratios vary by application: 1:1000-1:8000 for WB, 1:250-1:1000 for IHC, and 1:50-1:500 for IF/ICC applications . For each experimental system, researchers should perform titration experiments to determine optimal antibody concentrations, as effectiveness can be sample-dependent.

What cellular and tissue samples have been validated for RGS12 antibody detection?

RGS12 antibody has been successfully validated in multiple cell types and tissues:

For IHC applications, antigen retrieval is recommended with TE buffer pH 9.0, though citrate buffer pH 6.0 may also be used as an alternative . When examining RGS12 expression in novel cell types or tissues, these validated samples serve as useful positive controls.

What is the expected molecular weight for RGS12 detection in Western blots?

When using RGS12 antibody in Western blot applications, researchers should expect to detect bands between 140-150 kDa, although the calculated molecular weight is 156 kDa . This discrepancy between calculated and observed weights is not uncommon for proteins and may reflect post-translational modifications or protein folding characteristics. When validating a new RGS12 antibody, comparison with this expected size range serves as an important quality control parameter.

How can researchers validate RGS12 knockdown or overexpression in experimental models?

For RGS12 knockdown validation, researchers can use short hairpin RNA (shRNA) with target sequences such as 5′-GGACCTCAGCACTCGAGAAAG-3′ inserted into appropriate vectors like pShuttle-CMV plasmids . Non-specific sequences (e.g., 5′-TTCTCCGAACGTGTCACGT-3′) serve as important negative controls. For overexpression studies, the complete coding region of RGS12 can be cloned into expression vectors such as pDC315 plasmids .

Validation of successful knockdown or overexpression should employ multiple methods:

• Western blotting using validated RGS12 antibodies (e.g., 1:1000 dilution)

• qRT-PCR using primers designed for RGS12 mRNA sequence elements

• Functional assays relevant to RGS12's known activities (e.g., G-protein signaling)

For qRT-PCR analysis, employ the SYBR green dye technique with appropriate housekeeping genes such as 18s rRNA and GAPDH for relative quantification using the ΔΔCt method .

How is RGS12 implicated in oxidative stress pathways and what experimental approaches can investigate this connection?

Recent research has established that RGS12 plays a significant role in oxidative stress pathways, particularly in myocardial ischemia/reperfusion injury (MIRI) models. In cellular hypoxia/reoxygenation (H/R) experiments, RGS12 knockdown reduces oxidative stress markers, including decreased reactive oxygen species (ROS) levels and malondialdehyde activity, while increasing the activities of protective enzymes like superoxide dismutase and catalase .

To investigate this connection, researchers can employ:

• RGS12 knockdown or overexpression in relevant cell models (e.g., HL-1 cardiomyocytes)

• Measurement of oxidative stress markers before and after manipulation

• Assessment of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway components, which have anti-oxidative stress capacities

Experimental evidence indicates that RGS12 silencing activates the Nrf2 pathway, suggesting a mechanistic link between RGS12 and oxidative stress regulation that can be further explored using the RGS12 antibody for expression analysis .

What is the relationship between RGS12 and ferroptosis, and how can researchers investigate this connection?

RGS12 has been implicated in ferroptosis regulation, a form of programmed cell death characterized by iron-dependent lipid peroxidation. In MIRI models and H/R-stimulated HL-1 cells, increased ferroptosis was observed, while RGS12 knockdown reversed these changes .

To investigate this relationship, researchers can:

• Assess ferroptosis markers after RGS12 manipulation, including:

  • Fe2+ levels

  • Lipid ROS measurements

  • Expression of glutathione peroxidase 4 (GPX4)

  • Levels of cystine transporter solute carrier family 7 member 11 (SLC7A11)

  • Mitochondrial structural integrity (particularly cristae)

• Employ RGS12 antibody in Western blot and immunocytochemistry applications to correlate RGS12 expression with ferroptotic events

Experimental data shows that post-RGS12 silencing, Fe2+ and lipid ROS levels decrease while GPX4 and SLC7A11 expression increases, accompanied by improved mitochondrial structure through prevention of mitochondrial crest loss .

How can RGS12 antibody be used to study the interaction between RGS12 and the Nrf2 pathway?

The RGS12 antibody can be instrumental in elucidating the mechanistic relationship between RGS12 and the Nrf2 pathway, which has both anti-ferroptosis and anti-oxidative stress capabilities. Research has demonstrated that RGS12 knockdown activates the Nrf2 pathway, while RGS12 overexpression has the opposite effect .

Experimental approaches using RGS12 antibody include:

• Co-immunoprecipitation studies to identify potential physical interactions between RGS12 and Nrf2 pathway components

• Western blot analysis to quantify changes in Nrf2 pathway protein levels following RGS12 knockdown or overexpression

• Immunofluorescence microscopy to visualize potential co-localization of RGS12 with Nrf2 pathway proteins

• Chromatin immunoprecipitation (ChIP) assays to determine if RGS12 influences Nrf2 binding to antioxidant response elements

Researchers should optimize antibody dilutions for each application and include appropriate positive and negative controls to ensure valid interpretation of results.

What troubleshooting strategies are recommended when RGS12 detection is suboptimal in Western blot applications?

When RGS12 detection via Western blot is problematic, consider the following troubleshooting strategies:

• Antibody concentration adjustment: While the recommended dilution range is 1:1000-1:8000, sample-dependent optimization may be necessary. Try a dilution series experiment to determine optimal concentration .

• Protein extraction optimization: RGS12 is a relatively large protein (140-150 kDa observed); ensure complete extraction using RIPA buffer with protease inhibitors. Consider sonication on ice prior to clarification by centrifugation at 20,000 × g for 15 minutes .

• Gel percentage selection: For large proteins like RGS12, use 4-16% pre-cast SDS-polyacrylamide gels to ensure proper resolution .

• Transfer optimization: Extend transfer time or reduce voltage for complete transfer of large molecular weight proteins.

• Detection system sensitivity: Consider using enhanced chemiluminescence substrates like SuperSignal West Dura Extended Duration Substrate for improved sensitivity .

• Positive control inclusion: Include lysates from validated cell types like HepG2, A431, or SH-SY5Y cells as positive controls .

How can researchers address non-specific binding when using RGS12 antibody in immunofluorescence applications?

When non-specific binding occurs in immunofluorescence applications with RGS12 antibody:

• Optimize blocking conditions: Extend blocking time (1-2 hours) using 5-10% normal serum from the species of the secondary antibody.

• Adjust antibody dilution: While 1:50-1:500 is recommended, start with higher dilutions (1:500) and decrease if necessary .

• Include appropriate controls:

  • Omit primary antibody (secondary antibody only)

  • Use isotype control antibodies

  • Include a validated positive control like PC-3 cells

• Add carrier proteins: Include 1-3% BSA in antibody diluent to reduce non-specific binding.

• Optimize washing steps: Increase number and duration of washes with PBS containing 0.05-0.1% Tween-20.

• Use antigen pre-adsorption: Pre-incubate antibody with purified antigen to confirm specificity.

These approaches should be systematically tested to determine which combination provides optimal specific binding while minimizing background.

What is the emerging role of RGS12 in myocardial ischemia/reperfusion injury (MIRI)?

Recent research published in January 2025 has identified RGS12 as a significant factor in myocardial ischemia/reperfusion injury (MIRI) . Key findings include:

• RGS12 is highly expressed in both myocardial tissues of mice with MIRI and HL-1 cells subjected to hypoxia/reoxygenation (H/R).

• RGS12 knockdown reduces oxidative stress under pathological conditions, evidenced by:

  • Decreased reactive oxygen species (ROS) levels

  • Reduced malondialdehyde activity

  • Increased activities of protective enzymes (superoxide dismutase and catalase)

• RGS12 silencing decreases ferroptosis markers:

  • Reduced Fe2+ levels

  • Decreased lipid ROS

  • Increased expression of glutathione peroxidase 4 and cystine transporter SLC7A11

  • Improved mitochondrial structure

• Mechanistically, RGS12 appears to modulate the Nrf2 pathway, with knockdown activating this protective pathway that has both anti-ferroptosis and anti-oxidative stress capabilities.

• Penehyclidine hydrochloride (PHC), which blocks the MIRI process, decreases RGS12 expression both in vivo and in vitro, while RGS12 overexpression inhibits PHC's therapeutic effects .

These findings suggest that RGS12 antibodies will be increasingly important for studying cardiac pathology and potential therapeutic interventions.

How can adenoviral vector systems be optimized for RGS12 expression manipulation in research models?

For researchers seeking to manipulate RGS12 expression in experimental models, optimized adenoviral vector systems have proven effective. Based on recent methodologies:

• For RGS12 knockdown:

  • Use shRNA with validated sequences (e.g., 5′-GGACCTCAGCACTCGAGAAAG-3′)

  • Insert into pShuttle-CMV plasmids

  • Transfect 25 μg shuttle plasmids into 293A cells using Lipofectamine 3000 and P3000

• For RGS12 overexpression:

  • Clone the coding region of RGS12 into pDC315 plasmids

  • Transfect 27 μg plasmids (shuttle plasmid:skeleton plasmid=1:2) into 293A cells

  • Use Lipofectamine 3000 (41.8 μl) and P3000 (54 μl)

• For in vivo applications:

  • Collect viral particles after approximately 14 days

  • Concentrate to approximately 1×10¹¹ plaque-forming units/ml

  • For cardiac applications, inject 30 μl into the left ventricular free wall 72 hours prior to experimental intervention

• Validation strategies:

  • Use RGS12 antibody in Western blot to confirm protein expression changes

  • Perform qRT-PCR to verify mRNA alteration

  • Include appropriate control vectors in all experiments

This methodology has been successfully employed in MIRI models and represents a robust approach for investigating RGS12 function in various physiological and pathological contexts.

What is the potential therapeutic significance of targeting RGS12 in oxidative stress-related pathologies?

The emerging understanding of RGS12's role in oxidative stress and ferroptosis suggests significant therapeutic potential for targeting this protein. Recent research demonstrates that:

• RGS12 appears to be a target of penehyclidine hydrochloride (PHC), which has protective effects in myocardial ischemia/reperfusion injury .

• PHC decreases RGS12 expression levels both in vivo and in vitro, suggesting a potential mechanism for its therapeutic action .

• RGS12 overexpression inhibits the therapeutic effects of PHC on MIRI, further confirming their mechanistic relationship .

• The connection between RGS12 and the Nrf2 pathway provides potential for intervention, as Nrf2 activation confers both anti-ferroptosis and anti-oxidative stress capabilities.

For researchers investigating therapeutic applications, the RGS12 antibody serves as a critical tool for:

• Screening potential drug candidates that modulate RGS12 expression or activity

• Validating target engagement in therapeutic intervention studies

• Monitoring RGS12 levels as a biomarker in disease models and potential clinical samples

• Understanding the molecular mechanisms of RGS12-targeted therapies

These findings suggest that RGS12 inhibition may represent a novel therapeutic strategy for conditions characterized by excessive oxidative stress and ferroptosis, including ischemia-reperfusion injuries beyond the myocardium.